MANS Peptide Inhibits Inflammatory Mediator Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regulate the release of inflammatory mediators from inflammatory cells, contributing to tissue damage in conditions like asthma, COPD, and cystic fibrosis, as they do not fully describe the regulatory molecules and pathways involved in exocytotic processes.
Innovation Solution
The use of a 24-amino acid peptide sequence derived from the N-terminus of the MARCKS protein, specifically the MANS peptide, which competes with native MARCKS protein for membrane binding, thereby inhibiting the release of inflammatory mediators from inflammatory leukocytes by blocking degranulation pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to regulate inflammatory mediator release, then the release can be partially controlled, but the regulation is insufficient and leads to tissue damage in conditions like asthma, COPD, and cystic fibrosis
Solution Approach 1:
The patent introduces an exogenous peptide that acts as an intermediary substance to block the binding between native MARCKS protein and phospholipids. This peptide interferes with the normal exocytotic process, preventing inflammatory mediators from being released while avoiding direct tissue damage. The peptide serves as a mediating agent that disrupts the harmful pathway without causing additional harm to tissues.
Solution Approach 2:
The patent applies preliminary anti-action by providing a peptide that pre-blocks the MARCKS protein binding site on phospholipids before the natural exocytotic process can occur. This preventive approach stops the release of inflammatory mediators at an early stage, preventing tissue damage before it can happen rather than treating damage after it occurs.
2Ease of operation
If the MARCKS protein is used for its normal function in regulating exocytosis, then inflammatory mediator release can be controlled, but the specific regulatory mechanism is not fully understood and cannot be reliably targeted
Solution Approach 1:
The patent extracts the critical functional region of the MARCKS protein (the N-terminal 24 amino acid sequence) and uses it to create a simplified peptide block. This extraction approach isolates the essential binding motif from the complex full protein, making it easier to target and control the exocytotic process without needing to understand or manipulate the entire MARCKS protein pathway.
Solution Approach 2:
The patent creates a simplified copy of the critical MARCKS binding region in the form of a short peptide. This peptide copy retains the ability to bind to phospholipids and block the exocytotic pathway, providing an easier-to-manipulate tool for controlling inflammatory mediator release without requiring knowledge of the complete regulatory pathway.
3Reliability
If exogenous substances are used to block degranulation, then inflammatory mediator release can be inhibited, but the mechanism of action is not fully described and may have unintended effects
Solution Approach 1:
The patent applies local quality by designing a peptide that specifically targets the phospholipid binding site on the cell membrane, rather than acting globally on all cellular processes. The peptide's structure is optimized to bind only at the specific location where MARCKS normally interacts with phospholipids, providing localized inhibition of exocytosis without affecting other cellular functions.
Solution Approach 2:
The patent changes the molecular parameters of the binding interaction by using a peptide with specific amino acid sequences (N-terminal 24 amino acids of MARCKS) that mimic the phospholipid binding characteristics of the full protein. This parameter change allows the peptide to occupy the binding site and prevent degranulation while simplifying the mechanism to a straightforward competitive binding interaction.
Data Source
AI summary
The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.